ViroPharma to Host Conference Call to Discuss Clinical Results of HCV-796

Exton, Pennsylvania, UNITED STATES


EXTON, Pa., Nov. 10, 2005 (PRIMEZONE) -- ViroPharma Incorporated (Nasdaq:VPHM) today announced that the company will host a conference call and live audio webcast today at 4:30 p.m. to discuss the results of the Phase 1b study with HCV-796, an orally dosed hepatitis C (HCV) viral polymerase inhibitor with the potential to interfere with the replication of HCV, that is being co-developed with Wyeth Pharmaceuticals, a division of Wyeth.

During the conference call, ViroPharma management will discuss the results, and answer questions regarding all areas of the business.

The live webcast of the conference call will be accessible via ViroPharma's corporate website at http://www.viropharma.com. An audio archive will be available at the same address until November 24, 2005. To participate in the conference call, please dial 800-391-2548 (domestic) and 302-709-8328 (international). After placing the call, please tell the operator you wish to join the ViroPharma investor conference call.

About ViroPharma Incorporated

ViroPharma Incorporated is committed to the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings. ViroPharma commercializes Vancocin(R) approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains (for prescribing information, please download the package insert at http://www.viropharma.com/docs/pulvules_pi.pdf). ViroPharma currently focuses its drug development activities in viral diseases including cytomegalovirus (CMV) and hepatitis C (HCV). For more information on ViroPharma, visit the company's website at www.viropharma.com.


        

Contact Data